IMM Launches Video Newsletters

What’s New at IMM for 2025? Our recent updates spotlight a major rollout: Medication Risk Assessments are now being integrated across all claims, particularly those entering the 12 to 26-week stage. This is about smarter intervention—earlier, targeted, and pharmacist-led.

We're not here to manage the claim. That’s your expertise. We're here to identify and manage the medication risks—flagging high-risk and complex cases that may require IMEs, GP engagement, or other clinical interventions.

Let’s streamline the workflow:

• We identify the risk
• You coordinate the response
• Together, we improve outcomes

Why Follow-Ups Matter Too often, doctors agree to change something—but the change never happens. Whether it’s patient resistance, clinical uncertainty, or lack of follow-through, without a structured follow-up, momentum is lost.

A one-off assessment doesn’t fix a medication issue. Follow-ups ensure:

• Doctors are accountable for agreed changes
• Barriers are addressed early
• Medication plans stay on track

We typically recommend follow-ups at 3, 6, or 12 months, depending on the case. A 3-month window often meant the patient has been seen by their GP 4–6 times within this period, ample opportunities to implement pharmacist recommendations.

Let’s Keep It Simple You read enough every day, emails, reports, messages. That’s why we’re going all-in on video newsletters.

Bite-sized monthly updates

Focused on one or two key topics

Tailored to what you want to hear about

Got something you want covered next month? Let us know at 📧 admin@imedmanagement.com.au 📞 02 4036 5333

We’re here to support you. Let’s keep making medication safer

https://youtu.be/O1NAXD7_9r4?si=kmjDfjhnPclP5dHb